(Press-News.org) Bethesda, MD (August 12, 2013) — Patients with diarrhea-predominant irritable bowel syndrome, or IBS-D, treated with eluxadoline achieved better clinical response and experienced more symptom improvement than those using placebo, according to a recent study in Gastroenterology, the official journal of the American Gastroenterological Association. Eluxadoline, which is currently in phase 3 trials, is under development as a potential treatment for IBS-D.
"There is a critical need for a safe and effective treatment for IBS-D, a disorder affecting approximately 10 to 15 percent of the population in Western counties," said Anthony Lembo, co-study author from Harvard Medical School, Center for Clinical and Translational Research in Gastrointestinal Motility, Beth Israel Deaconess Medical Center, Division of Gastroenterology, Boston, MA. "The results of our study confirm the effectiveness of eluxadoline to decrease abdominal pain and improve stool consistency, without significant risk of constipation, for patients with IBS-D."
This phase 2 study evaluated the effectiveness, safety and tolerability of orally administrated eluxadoline. Researchers randomly assigned 807 adult patients with IBS-D to 5 mg, 25 mg, 100 mg or 200 mg eluxadoline or placebo twice a day for 12 weeks. Patients given eluxadoline had significant symptom improvement with a very low incidence of constipation. Symptom relief and quality of life scores increased with time of treatment.
"Based on these promising results, additional clinical development of eluxadoline is warranted to validate its clinical meaningfulness and to determine what baseline patient characteristics are predictive of clinical response with eluxadoline," added Lembo. "We look forward to seeing how eluxadoline fares in phase 3 trials and hope to end suffering for IBS-D patients searching for an effective treatment."
###
IBS can negatively impact an individual's quality of life and result in significant medical costs. Current safe and effective pharmacologic treatments for IBS-D are limited and include antispasmodics, antidepressants, antidiarrheal agents and alosetron. Learn more about IBS in AGA's patient brochure.
Funding for this study was provided by Furiex Pharmaceuticals.
About the AGA Institute
The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to include 17,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization. http://www.gastro.org.
About Gastroenterology
Gastroenterology, the official journal of the AGA Institute, is the most prominent scientific journal in the specialty and is in the top 1 percent of indexed medical journals internationally. The journal publishes clinical and basic science studies of all aspects of the digestive system, including the liver and pancreas, as well as nutrition. The journal is abstracted and indexed in Biological Abstracts, Current Awareness in Biological Sciences, Chemical Abstracts, Current Contents, Excerpta Medica, Index Medicus, Nutrition Abstracts and Science Citation Index. For more information, visit http://www.gastrojournal.org.
Like AGA and Gastroenterology on Facebook.
Join AGA on LinkedIn.
Follow us on Twitter @AmerGastroAssn.
Check out our videos on YouTube. END
New IBS treatment shows potential in Phase 2 study
2013-08-12
ELSE PRESS RELEASES FROM THIS DATE:
Protein that delays cell division in bacteria may lead to the identification of new antibiotics
2013-08-12
In 1958 a group of scientists working in Denmark made the striking observation that bacterial cells are about twice as large when they are cultured on a rich nutrient source than when they are cultured on a meager one. When they are shifted from a nutrient-poor environment to a nutrient-rich one, they bulk up until they have achieved a size more appropriate to their new growth conditions.
It has taken 60 years to figure out how the bacteria are able to sample their surroundings and alter their cell cycles so that they grow to a size suited to the environment.
In 2007 ...
Tumor suppressor is needed for stem cells to mature into neurons
2013-08-12
CHD5 has previously been proposed as a tumour suppressor, acting as a brake that prevents healthy cells from developing into cancer cells. But the part played by the protein in healthy tissue, and whether this role is important for its ability to counter tumour growth, has remained largely uncharted. Working with colleagues at Trinity College in Dublin and BRIC in Copenhagen, researchers at Karolinska Institutet have revealed its function in normal nervous system development and as a tumour suppressor.
The recently published study shows that when stem cells approach the ...
Carnegie Mellon researchers say readers' identities can reveal much about content of articles
2013-08-12
PITTSBURGH -- Articles that people share on social networks can reveal a lot about those readers, research has shown. But a new Carnegie Mellon University study reverses the proposition, asking the question: What can be learned about an article from the attributes of its readers?
To find out, the CMU researchers, along with colleagues at the University of Washington, analyzed almost 3 million news articles and the public profiles of the people who shared those articles on Twitter. This enabled them to generate a few thousand "badges" that characterized the content of ...
Rice writes rules for gene-therapy vectors
2013-08-12
HOUSTON -- Rice University researchers are making strides toward a set of rules to custom-design Lego-like viral capsid proteins for gene therapy.
A new paper by Rice scientists Junghae Suh and Jonathan Silberg and their students details their use of computational and bioengineering methods to combine pieces of very different adeno-associated viruses (AAVs) to create new, benign viruses that can deliver DNA payloads to specific cells.
The research appears this month in the American Chemical Society journal ACS Synthetic Biology.
AAVs are found in nature and commonly ...
Onsite colposcopy clinic improves cancer screening rates: Study
2013-08-12
TORONTO, ON, August 12, 2013 – Women who had a colposcopy at a sexual health clinic that provided extra support and counselling were 34 per cent more likely to undergo the cancer screening procedure compared to women who were referred to a hospital or doctor's office, according to a new study by Women's College Hospital's Dr. Sheila Dunn.
Although colposcopy is an important component of cervical cancer screening, some women, particularly those who are disadvantaged, fail to attend colposcopy appointments. However, researchers in the study, published today in the Journal ...
Mayo Clinic: Preclinical tests may lead to new approach to treat CNS lymphoma
2013-08-12
JACKSONVILLE, Fla. -- A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, and eyes. The clinical trial, now open at the three campuses of Mayo Clinic -- in Florida, Minnesota and Arizona -- follows successful testing of the drug, pomalidomide, in mouse models of CNS lymphoma. Details of the preclinical testing are available in the science journal PLOS ONE.
Approximately 5,000 patients are diagnosed ...
Communicating nightingales: Older males trill better
2013-08-12
Older male nightingales perform faster and more demanding trills than their younger rivals. These findings were published by researchers at the University of Basel and the Netherlands Institute of Ecology in the online edition of Journal of Avian Biology. With up to 100 trill elements a second, nightingales belong to the fastest singers.
Nightingales are famous for their large song repertoire: Each male can perform around 200 different song types. Facing this great variety, how can a female listener assess correctly if the male counterpart is a suitable mating partner? ...
Competition changes how people view strangers online
2013-08-12
COLUMBUS, Ohio -- An anonymous stranger you encounter on websites like Yelp or Amazon may seem to be just like you, and a potential friend. But a stranger on a site like eBay is a whole different story.
A new study finds that on websites where people compete against each other, assumptions about strangers change.
Previous research has shown that people have a bias toward thinking that strangers they encounter online are probably just like them.
But when they are competitors, strangers are seen as different, and not sharing your traits and values -- and that changes ...
New materials for bio-based hydrogen synthesis
2013-08-12
Researchers at the Ruhr-Universität Bochum (RUB) have discovered an efficient process for hydrogen biocatalysis. They developed semi-synthetic hydrogenases, hydrogen-generating enzymes, by adding the protein's biological precursor to a chemically synthesized inactive iron complex. From these two components, the biological catalyst formed spontaneously in a test tube. "Extracting hydrogenases from living cells is highly difficult," says Prof Dr Thomas Happe, head of the work group Photobiotechnology at the RUB. "Therefore, their industrial application has always been a long ...
Simulating flow from volcanoes and oil spills
2013-08-12
WASHINGTON D.C. August 12, 2013 -- Some time around 37,000 BCE a massive volcano erupted in the Campanian region of Italy, blanketing much of Europe with ash, stunting plant growth and possibly dooming the Neanderthals. While our prehistoric relatives had no way to know the ash cloud was coming, a recent study provides a new tool that may have predicted what path volcanic debris would take.
"This paper provides a model for the pattern of the ash cloud if the wind is blowing past an eruption of a given size," said Peter Baines, a scientist at the University of Melbourne ...